Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) improve ADHD diagnosis timeframes, (b) reduce the waiting list for ADHD medication and (c) improve support for patients and their families whilst undergoing the diagnostic process in Bromsgrove and the Villages.

It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including provision of attention deficit hyperactivity disorder (ADHD) services, in line with relevant National Institute for Health and Care Excellence (NICE) guidelines.

The Herefordshire and Worcestershire ICB is committed to wait times for ADHD assessment of less than 18 weeks, however, there are known waits for children and young people to access ADHD diagnostic assessment services due to an increase in demand. There are currently 1,600 children and young people waiting for an assessment via an NHS provider, with an average wait time of 60 weeks. For adults, ADHD assessments are conducted by Right to Choose providers only and these services typically have a waiting time below the 18-week standard.

All patients, including children and young people, can access the Right to Choose pathway for ADHD assessments through their general practice, allowing them to select an alternative provider if the waiting time for NHS services exceeds 18 weeks at the point of referral. The ICB has put in place a number of contracts under Right to Choose to improve choice for patients and is working with its NHS commissioned services to reduce long waits. It has also commissioned additional capacity for those children waiting over 104 weeks in the NHS service in 2025/26 and will continue this in 2026/27.

For children, medication is provided by the NHS commissioned service, and the waiting time is six to eight weeks for first medication reviews, and four to six months to initiate medication following diagnosis. It should be noted that NICE guidelines expect non-pharmaceutical interventions to be considered before medication for all children. The ICB is investing in the local NHS commissioned service to increase medication treatment capacity. For adults, the only pathway available for ADHD assessments is Right to Choose. The ICB advises that there is no waiting list for these patients as they will automatically be initiated and titrated for medication, where that is identified as an appropriate treatment.

Furthermore, the ICB is at the end of a tendering process for a Neurodivergence Support Service for zero to 25 year olds and their families, and this should go live from September 2026. The ICB is considering commissioning a service for adults age 25 years old and over from April 2027.

More broadly, NHS England issued advice to systems on ADHD service delivery and prioritisation on 7 October 2025. This advice includes guidance on managing service provisions, reviewing waiting lists, and providing patient support. The advice can be found at the following link:

https://www.england.nhs.uk/long-read/adhd-service-delivery-and-prioritisation-advice-to-systems/

Through the NHS Medium-Term Planning Framework, published 24 October 2025, NHS England has set clear expectations for local ICBs and trusts to improve access, experience, and outcomes for ADHD services over the next three years, focusing on improving quality and productivity. The framework was explicit that ICBs and providers are expected to optimise existing resources to reduce long waits for ADHD assessments and improve the quality of assessments by implementing existing and new guidance, as published.